Research Associate II

DELFI Diagnostics to showcase whole-genome cfDNA platform advances in cancer detection and monitoring at AACR 2026 Annual Meeting. PR Newswire Today at 8:00am PDT Five poster presentations span lung cancer early detection, immunotherapy response prediction, cancer subtyping, treatment monitoring, and next-generation sequencing platforms PALO ALTO, Calif., April 6, 2026 /PRNewswire/ - DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage whole-genome cell-free DNA (cfDNA) assays for cancer detection and monitoring, today announced it will present five poster presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting, taking place April 17-22, 2026 in San Diego, CA. The presentations highlight advances across DELFI's platform, including lung cancer subtyping, immunotherapy response prediction, the clinical utility of ctDNA-based molecular response, treatment monitoring on ultra high-throughput, next-generation sequencing platforms, and colorectal cancer treatment response monitoring. "This year's AACR presentations reflect the breadth and maturity of our AI-driven, computational platform," said Susan Tousi, CEO. "From early detection to treatment monitoring, we're generating clinical evidence across the cancer continuum that reinforces the power of genome-wide cfDNA analysis combined with AI. These five abstracts represent meaningful contributions from our team and our academic collaborators at Johns Hopkins and the Netherlands Cancer Institute." Poster Presentations at AACR 2026 Sunday, April 19 | 2:00-5:00 PM PT Cell-Free DNA Fragmentome Profiles Predict Immunotherapy Response * Session: Liquid Biopsies: Circulating Nucleic Acids 1 * Poster Section 44, Board 15 | Abstract #1134 * Presenter: Valsamo Anagnostou, MD, PhD, Johns Hopkins University Lung Cancer Subtyping Using Cell-Free DNA Fragmentomes and Protein Biomarkers * Session: Liquid Biopsies: Circulating Nucleic Acids 1 * Poster Section 44, Board 16 | Abstract #1135 * Presenter: Laurel Millberg, MSc, DELFI Diagnostics Clinical Utility of Landmark ctDNA Molecular Response as an Early Indicator of Immunotherapy Outcomes in Lung Cancer * Session: Liquid Biopsy: Multi-Analyte and Multi-Omic * Poster Section 5, Board 17 | Abstract #110 * Presenter: Jaime Wehr, MS, Johns Hopkins University Monday, April 20 | 2:00-5:00 PM PT Enhanced cfDNA Fragmentation-Based Treatment Monitoring on the Ultima Genomics Platform * Session: Liquid Biopsies: Circulating Nucleic Acids 3 * Poster Section 45, Board 24 | Abstract #3863 * Presenter: Laurel Millberg, MSc, DELFI Diagnostics Tuesday, April 21 | 9:00 AM-12:00 PM PT Cell-Free DNA Fragmentomes for Treatment Response Monitoring in Patients with Metastatic Colorectal Cancer: The DOLPHIN Study * Session: Liquid Biopsies: Circulating Nucleic Acids 4 * Poster Section 45, Board 20 | Abstract #5325 * Presenter: Denise van Steijn, MSc, Netherlands Cancer Institute The five presentations reflect the expanding clinical evidence base for DELFI's technology platform, which uses AI and machine learning to analyze genome-wide patterns of cell-free DNA fragmentation in blood. The research spans early detection, cancer subtyping, immunotherapy response prediction, and treatment monitoring across multiple cancer types and sequencing platforms. In early detection, DELFI has clinically validated FirstLook Lung, a blood-based test designed to improve early detection of lung cancer, the leading cause of cancer death in the United States. New data being presented at AACR 2026 extend the platform's capabilities into lung cancer subtyping and immunotherapy response prediction, demonstrating how fragmentation patterns and protein biomarkers can provide clinical insights beyond initial detection. On the treatment-monitoring front, DELFI-TF*, the company's tumor-fraction-based monitoring solution, continues to generate clinical validation data across cancer types. The DOLPHIN study presentation describes a multicenter, prospective, observational study from the Netherlands Cancer Institute that examines new potential applications for cfDNA-based treatment response monitoring in ~500 colorectal cancer patients treated with systemic chemotherapy. Additionally, new DELFI-TF data generated on the Ultima Genomics platform underscore the adaptability of DELFI's core genomics technology and identify promising avenues for performance enhancement in future product generations. "We are excited to present our latest work in early detection, treatment monitoring, subtyping, and technology innovation, " said Amoolya Singh, PhD, Chief Technology Officer. "We continue to believe that the sensitivity, low cost, and versatility of our technical approach position us well for continued scientific discovery and product development." Attendees are invited to visit DELFI Diagnostics at Booth #1711 or request a meeting at https://about.delfidiagnostics.com/aacr2026/. For more information about DELFI's fragmentomics platform, visit www.delfidiagnostics.com. *The DELFI-TF Assay and related services are for Research Purposes Only and are not intended for diagnostic procedures or applications. About DELFI Diagnostics DELFI Diagnostics is developing next-generation, blood-based tests that are convenient, accessible, and reliable, offering a new way to help detect cancer. DELFI's proprietary technology leverages advanced AI to analyze patterns of circulating cell-free DNA fragments in the blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commercially available blood-based screening test for lung cancer in the United States, serves individuals eligible for lung cancer screening through a simple blood draw that integrates with routine blood work. With a negative predictive value of 99.8 percent, the test identifies individuals at elevated risk for lung cancer, including early-stage disease, and guides them toward follow-up with guideline-recommended low-dose CT. Through novel health system partnerships, DELFI is pioneering electronic medical record (EMR) integration that makes blood-based testing available to historically underserved populations. FirstLook Lung has not been cleared or approved by the FDA. DELFI-Tumor Fraction (DELFI-TF) is a liquid biopsy research service for monitoring late-stage cancer patients during their course of treatment. As a versatile precision medicine platform, DELFI-TF provides a non-invasive, tissue-free, and tumor-agnostic quantitative estimate of tumor burden at the time of the blood draw. Based on the standard DELFI cfDNA assay, DELFI-TF overcomes many of the barriers of currently available monitoring products such as cost, turnaround time, sensitivity, and tissue biopsy, while maintaining market-level performance. DELFI-TF provides critical therapeutic monitoring insights across all solid cancer and treatment types by establishing molecular profiles, tracking therapeutic effectiveness, and identifying emerging resistance patterns earlier than traditional methods. DELFI-TF has not been cleared or approved by the FDA and is intended for research use only. SOURCE DELFI Diagnostics This is a paid placement. For further inquiries, please contact PR Newswire directly.

DELFI Diagnostics appoints Cindy Soriano as Chief Financial Officer and announces participation in 44th Annual J.P. Morgan Healthcare Conference. News provided by. PALO ALTO, Calif., Jan. 8, 2026 /PRNewswire/ - DELFI Diagnostics, Inc., developer of accessible blood-based, liquid biopsy tests that deliver a new way to enhance early cancer detection, today announced the appointment of Cindy Soriano as Chief Financial Officer, effective immediately. The company also announced that Chief Executive Officer, Susan Tousi, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. "Cindy's promotion comes at a pivotal moment for DELFI as we prepare to achieve key clinical and regulatory milestones," said Susan Tousi. "Over the past three and a half years as Vice President of Finance and Investor Relations, Cindy has been instrumental in building our financial foundation and guiding us through two successful fundraising rounds. Her strategic vision, operational rigor, and collaborative approach will be essential as we work to deliver on our mission and create long-term value." Cindy brings 20 years of finance leadership to the role. Prior to joining DELFI, Cindy held senior finance leadership roles across the life sciences sector, including leading the finance organization at Zogenix through its acquisition by UCB and post-transaction integration. Earlier, she held various leadership roles at BioMarin Pharmaceuticals supporting operational and strategic planning across a diverse portfolio of assets spanning pre-clinical, clinical, and commercial stages. J.P. Morgan Healthcare Conference Presentation Susan Tousi, CEO, is scheduled to present on Thursday, January 15, 2026, at 9:30 a.m. PT at the Westin St. Francis hotel in San Francisco. The presentation will provide an update on DELFI's progress and strategic priorities. About DELFI Diagnostics DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals' cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. To learn more about DELFI Diagnostics, visit DELFIDiagnostics.com. SOURCE DELFI Diagnostics